Please use this identifier to cite or link to this item:
Title: Effects of sacubitril/valsartan on functional status and exercise capacity in real-world patients
Authors: Lau, Chirik Wah
MARTENS, Pieter 
Lambeets, Seppe
DUPONT, Matthias 
MULLENS, Wilfried 
Issue Date: 2019
Source: ACTA CARDIOLOGICA, 74(5), p. 405-412
Abstract: Background: Sacubitril/valsartan significantly reduced heart failure(HF) hospitalisations and mortality in the PARADIGM-HF-trial. However real-world data on symptomatic and functional improvement are lacking. Methods: Between December 2016 and January 2018, we retrospectively collected baseline and follow-up data including New York Heart Association (NYHA)-functional class and Cardio-pulmonary exercise data(CPET) in all HF-patients receiving sacubitril/valsartan. Additionally, in patients with an implantable electric cardiovascular device (IECD) enrolled in remote telemonitoring, we quantified patient level activity before and after initiation. Results: A total of 201 patients (82% males) were identified. NYHA-functional class was reassessed after an average of 221 +/- 114 days. Overall, 3.3% of patients improved 2 NYHA classes, 28.7% improved 1 NYHA class, 64% remained stable and 4% deteriorated 1 NYHA class. Patients with symptomatic improvement exhibited a larger reduction in Left Ventricular End Systolic Volume(LVESV) and a larger increase in Left Ventricular Ejection Fraction(LVEF[p-value both <.05]). In total, 110 patients (55%) were equipped with an IECD capable of quantifying outpatient activity-level. On an average of 364 days before sacubitril/valsartan, an activity expressed as %-of-the-day was 13 +/- 2%, vs. 18 +/- 3% the 364 days following sacubitril/valsartan initiation. Signifying a 38% improvement in the out-patient activity level. CPET-data was obtained in paired-fashion in 45 patients (22%). VO2max at baseline (14.7 +/- 3.8 mL/kg/min) did not significantly change at follow-up (14.1 +/- 4.7 mL/min/kg; p = .237). Conclusion: Real-world patients exhibit significant symptomatic and functional improvement following the initiation of sacubitril/valsartan. However, larger prospective studies are necessary to assess the impact of sacubitril/valsartan on indices of maximal exercise performance measured during CPET.
Notes: [Lau, Chirik Wah; Martens, Pieter; Lambeets, Seppe; Dupont, Matthias; Mullens, Wilfried] Ziekenhuis Oost Limburg, Dept Cardiol, Schiepse Bos 6, B-3600 Genk, Belgium. [Martens, Pieter] Hasselt Univ, Doctoral Sch Med & Life Sci, Diepenbeek, Belgium. [Mullens, Wilfried] Hasselt Univ, Fac Med & Life Sci, Biomed Res Inst, Diepenbeek, Belgium.
Keywords: Sacubitril/valsartan; cardiopulmonary exercise test; NYHA functional class; functionality; real world;Sacubitril; valsartan; cardiopulmonary exercise test; NYHA functional class; functionality; real world
Document URI:
ISSN: 0001-5385
e-ISSN: 1784-973X
DOI: 10.1080/00015385.2018.1521054
ISI #: 000487298100006
Rights: 2018 Belgian Society of Cardiology
Category: A1
Type: Journal Contribution
Validations: ecoom 2020
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
  Restricted Access
Published version1.02 MBAdobe PDFView/Open    Request a copy
Show full item record


checked on Sep 2, 2020


checked on May 21, 2022

Page view(s)

checked on May 22, 2022


checked on May 22, 2022

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.